Rock Springs Capital, Logos Capital, Woodline, and Acuta Capital, amongst others. The cash will be used for further clinical development of Enliven’s two lead candidates, BCR-ABL inhibitor ELVN ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback